What is the recommended long‑term treatment strategy for a patient with autoimmune hemolytic anemia (AIHA)?

Long-Term Treatment Strategy for Autoimmune Hemolytic Anemia (AIHA)

For warm AIHA (wAIHA), rituximab has emerged as the preferred second-line therapy for relapsed or refractory disease after initial corticosteroid treatment, with splenectomy now reserved for later lines; for cold agglutinin disease (CAD), rituximab with or without bendamustine is first-line, with complement inhibitors like sutimlimab as established alternatives.

Treatment Algorithm by AIHA Subtype

Warm AIHA (wAIHA) - 60-70% of cases

First-Line Therapy:

• Corticosteroids remain the standard initial treatment, with over 85% response rate but less than one-third maintaining response upon weaning 1
• Prednisone 0.5-2 mg/kg/day for 2-4 weeks, with rapid taper to avoid corticosteroid-related complications 1
• Critical caveat: The detrimental effects of prolonged corticosteroids often outweigh benefits, so avoid maintenance doses when possible 1

Second-Line Therapy (Relapsed/Refractory):

• Rituximab is now the preferred option, providing complete remission in over 75% of patients failing corticosteroids, with potentially long-lasting responses 1
• This represents a paradigm shift: rituximab should be considered early in severe cases and if no prompt response to steroids is achieved 2
• The evidence from 2020-2025 consistently supports rituximab over traditional splenectomy as second-line 3, 1, 4

Third-Line Options:

• Splenectomy: Now deferred when possible but offers long-term remission in over two-thirds of patients 1
• Immunosuppressants (azathioprine, mycophenolate mofetil, cyclosporine): Over 50% response rate in rituximab failures 1
• Erythropoiesis-stimulating agents: Particularly useful when reticulocytopenia/inadequate bone marrow compensation is present 4

Emerging Therapies for Refractory Cases:

• Fostamatinib (spleen tyrosine kinase inhibitor): Shows promise in treatment-refractory disease 1, 5
• BTK inhibitors (rilzabrutinib, ibrutinib): Target B-cell receptor signaling 6, 4
• FcRn inhibitors (nipocalimab): Disrupt IgG recycling 1, 4
• Plasma cell-directed therapies (bortezomib, daratumumab): For refractory cases 4, 5

Cold Agglutinin Disease (CAD) - 20-25% of cases

Critical distinction: CAD is now recognized as a chronic clonal lymphoproliferative disorder, fundamentally different from wAIHA 7

First-Line Therapy:

• Rituximab with or without bendamustine is the established first-line for patients requiring therapy 2
• Corticosteroids and splenectomy are ineffective in CAD - this is a critical pitfall to avoid 3, 8

Established Alternative:

• Sutimlimab (complement C1s inhibitor): FDA-approved for CAD, targets the classical complement pathway 3, 6

Emerging Options:

• Novel anti-C1s antibodies (riliprubart): Extended half-life due to enhanced neonatal Fc receptor affinity 6
• BTK inhibitors: Target the underlying lymphoproliferative disorder 6, 5

Special Considerations for Long-Term Management

Secondary AIHA (50% of cases)

When AIHA is secondary to lupus, lymphoproliferative disorders, or other conditions, treatment follows similar principles but must address the underlying disease 9, 4:

• In SLE-associated AIHA: Moderate/high-dose corticosteroids combined with immunosuppressants (azathioprine, mycophenolate, cyclosporine), with rituximab for refractory cases 9
• Initial therapy with IV methylprednisolone pulses (1-3 days) is encouraged 9

Supportive Care Throughout Treatment

• Transfusions: When anemia is clinically significant, despite compatibility challenges 4
• Prophylactic anticoagulation: For severe hemolysis due to thrombotic risk 4
• Recombinant erythropoietin: When reticulocytopenia or inadequate bone marrow compensation is present 7, 4
• Vitamin supplementation: Essential supportive measure 7

Monitoring for Relapse

• AIHA frequently has a relapsing course, particularly during corticosteroid tapering 9
• Treatment is typically lengthy, requiring vigilant monitoring 9

Key Pitfalls to Avoid

1. Prolonged corticosteroid use: Rapidly taper and stop in non-responders after 4 weeks to avoid complications outweighing benefits 10, 1
2. Using steroids/splenectomy for CAD: These are ineffective and delay appropriate therapy 3, 8
3. Delaying rituximab in wAIHA: Early consideration prevents excessive corticosteroid exposure 1, 2
4. IV anti-D in AIHA: Should be avoided to prevent exacerbation of hemolysis 10

Evidence Quality Note

The strongest recent evidence comes from the 2020 First International Consensus Meeting 2 and 2022-2025 comprehensive reviews 1, 4, 5, which consistently support the shift toward rituximab as preferred second-line for wAIHA and first-line for CAD. The 2019 EULAR guidelines 9 provide additional support for this approach in secondary AIHA contexts.